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Abstract
The identification of mutations and deletions in the SMARCB1 locus in chromosome band 22q11.2 
in pediatric rhabdoid tumors provided the first evidence for the involvement of the SWI/SNF 
chromatin remodeling complex in cancer. Over the last 15 years, alterations in more than 20 
members of the complex have been reported in a variety of human tumors. These include germline 
mutations and copy number alterations in SMARCB1, SMARCA4, SMARCE1, and PBRM1 that 
predispose carriers to both benign and malignant neoplasms. Somatic mutations, structural 
abnormalities, or epigenetic modifications that lead to reduced or aberrant expression of complex 
members have now been reported in more than twenty percent of malignancies, including both 
solid tumors and hematologic disorders in both children and adults. In this review, we will 
highlight the role of SMARCB1 in cancer as a paradigm for other tumors with alterations in 
SWI/SNF complex members and demonstrate the broad spectrum of mutations observed in 
complex members in different tumor types.
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Recent studies have established that cancer development depends on epigenetic alterations 
as well as genomic changes [Choi and Lee, 2013; Feinberg, 2014]. Multiple reports have 
demonstrated roles for altered DNA methylation, histone modifications and microRNA 
expression in the etiology of a wide variety of human cancers [Sarkar et al., 2013; 
Waldmann and Schneider, 2013]. The perturbation of SWI/SNF chromatin remodeling 
complexes is an emerging theme in cancer initiation and progression [Narlikar et al., 2013] 
and it is now postulated that at least 20% of all human tumors contain mutations in at least 
one member of the SWI/SNF complex [Kadoch et al., 2013]. In this review, we will 
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specifically highlight those subunits that demonstrate germline alterations and predispose 
individuals to benign and malignant neoplasms.
SWI/SNF chromatin remodeling complexes regulate critical cellular processes including cell 
cycle progression, programmed cell death, differentiation, genomic instability and DNA 
repair [Narlikar et al., 2013]. The SWI/SNF complex, first discovered in S. cerevisiae, 
shows strong conservation from yeast to Drosophila to mammals and contains 
approximately 12–28 components [Kadoch et al., 2013; Yaniv, 2014]. The complex, 
containing one of 2 mutually exclusive ATPase subunits, BRG1/SMARCA4 or BRM/
SMARCA2, physically alters nucleosome positioning using energy generated by ATP 
hydrolysis. The complexes can be subdivided into two broad categories, BAF or PBAF 
(Figure 1), based upon the presence of the ARID1A/B subunits, or ARID2 and PBRM1 
subunits, respectively [Kadoch et al., 2013; Wei and Weissman, 2014]. Depending upon the 
configuration of complex components, SWI/SNF complexes can carry out a variety of 
cellular functions including neural differentiation [Lessard et al., 2007], embryonic stem cell 
differentiation [Ho et al., 2009], hepatic lipid metabolism [Li et al., 2008], glucose 
metabolism [Meng et al., 2013] and brain development [Tuoc et al., 2013]. However, the 
mechanisms that determine the types of cancers associated with inactivation of different 
complex members and how their losses fuel transformation remain undetermined.
SMARCB1 alterations and rhabdoid tumor
Rhabdoid tumors are rare pediatric malignancies that most often arise in the brain, kidney 
and soft tissues. The peak incidence is in the first several years of life, although we have 
studied congenital tumors that arise during fetal development and tumors that have 
presented in late adulthood. Regardless of the anatomic location, rhabdoid tumors are highly 
aggressive malignancies, and combined approaches using surgery, chemotherapy and/or 
radiation are required for treatment [Hilden et al., 2004]. Although the tumors may be 
rapidly fatal, individual case reports have described patients who have survived for up to 26 
years with multiple recurrences [Takahashi-Fujigasaki et al., 2012]. The identification of 
deletions and mutations in the SMARCB1/INI1/BAF47/hSNF5 locus, hereafter referred to as 
SMARCB1, in pediatric rhabdoid tumors [Versteege et al., 1998] served as a paradigm for 
how genetic alterations in chromatin-remodeling complex subunits might play a role in 
tumor development. The identification of germline mutations in SMARCB1 [Biegel et al., 
1999], accompanied by loss of the normal allele, confirmed that rhabdoid tumorigenesis 
followed the classic two-hit model for a tumor suppressor gene.
Germline and acquired alterations of SMARCB1 and rhabdoid tumor
The SMARCB1 locus is located in chromosome band 22q11.2, distal to the region that is 
typically deleted in DiGeorge and Velo-cardio-facial syndromes. The alterations in 
SMARCB1 include intragenic and whole gene deletions, intragenic duplications, and 
mutations. The molecular characterization of two large cohorts of patients with rhabdoid 
tumors has been reported [Eaton et al., 2011; Bourdeaut et al., 2011] which revealed an 
overall incidence of germline alterations of SMARCB1 in 35% of patients. Virtually all 
patients with two primary tumors have a germline mutation or deletion of SMARCB1, 
Biegel et al. Page 2













however the incidence is also high in children with primary brain tumors (atypical teratoid/
rhabdoid tumor; AT/RT) and renal tumors. In contrast, extra-renal rhabdoid tumors are 
typically associated with bi-allelic, somatic deletions of SMARCB1. A summary of the 
germline alterations in SMARCB1 in 70 rhabdoid tumor patients studied from one of the 
author’s laboratory is shown in Figure 2. The percentages of patients with whole gene 
deletions (22%), intragenic deletions and duplications (24%), nonsense mutations (24%) and 
frameshift mutations (20%) were similar. However, unlike other tumor suppressor genes, 
such as TP53 and WT1, there were no missense mutations, and only 10% of the patients had 
splice-site mutations. The second inactivating event in the tumors from these individuals is 
typically a deletion of the remaining copy of SMARCB1, or a copy number neutral loss of 
heterozygosity event that results in duplication of the mutated allele. The types of mutations 
in sporadic tumors are similar to those observed in the germline; essentially all copy number 
alterations or truncating mutations. Missense mutations are virtually absent and splice site 
mutations are uncommon.
The vast majority of germline deletions and mutations appear de novo, due in part to the 
fatal nature of the disease. Several families have been reported with two or more affected 
siblings in which there is presumed gonadal mosaicism, and two of our patients 
demonstrated germline mosaicism for a single exon deletion. While a few multi-generation 
families have been described with an appearance of some reduced penetrance, no established 
risk estimates for cancer in SMARCB1 mutation carriers exists. This has become an 
increasingly difficult issue in providing genetic counseling for families in which an 
individual is found to have a deletion in SMARCB1 as part of a contiguous 22q11.2 deletion 
syndrome, but who does not have a tumor. As whole exome and ultimately whole genome 
sequencing studies become established as clinical diagnostic tests, the identification of 
SMARCB1 mutations as an incidental finding will increase. Without established risk 
estimates for cancer in unaffected carriers, it will be challenging to provide guidance for 
cancer surveillance over an individual’s lifetime. Furthermore, as presented in the 
accompanying articles in this special issue, and as shown in Figure 1, the number of genes in 
the SWI/SNF and other chromatin remodeling complexes mutated in genetic disorders such 
as Coffin-Siris or Nicolaides-Baraitser syndrome, autism spectrum disorders and intellectual 
disability is also increasing. The current inability to predict the phenotype associated with 
mutations or deletions in these genes will be particularly challenging in a prenatal or 
neonatal setting.
SMARCB1 alterations and schwannomatosis
As shown in Table 1 and reviewed by Smith et al. [Smith et al., 2014], germline mutations 
in SMARCB1 are also seen in association with schwannomatosis, in which affected 
individuals develop multiple, benign nerve sheath tumors (schwannomas). Approximately 
45% of patients with familial schwannomatosis and 9% of patients with apparently sporadic 
schwannomas have germline mutations in SMARCB1. However, in contrast to the whole 
gene deletions and truncating mutations observed in in rhabdoid tumor patients, the 
mutations in schwannomatosis are primarily splice site mutations and missense mutations in 
exons 1 and the 3’UTR [Hulsebos et al., 2007; Hadfield et al., 2008; Rousseau et al., 2011; 
Smith et al., 2012; Smith et al., 2014]. To date, one patient with a missense mutation in exon 
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9 of SMARCB1, who has both schwannomatosis and Coffin-Siris syndrome (Gossai et al, in 
preparation), has been reported. These studies suggest that loss of function truncating 
mutations and whole gene deletions are associated with more aggressive tumors, including 
rhabdoid tumors and malignant peripheral nerve sheath tumors. These tumors most often 
arise during infancy and early childhood. In contrast, germline missense mutations are more 
often associated with developmental disorders and late onset, typically benign tumors. We 
have described several families [Eaton et al., 2011; Carter et al., 2012] in which the identical 
truncating mutation led to a rhabdoid tumor in a young child, and the development of 
schwannomas in the adult carrier(s) in the previous generation. This led to the hypothesis 
that an early developmental window occurs in which the risk for rhabdoid tumors is highest, 
consistent with the peak incidence at 6 months of age in germline mutation carriers. After 
three years of age, the incidence dramatically decreases [Eaton et al., 2011]. Therefore, the 
cells of origin for rhabdoid tumor and schwannoma may differ, with the nature of the 
SWI/SNF complexes in those cells dictating the morphology and clinical behavior of the 
resulting neoplasms.
In addition to the germline mutations reported in rhabdoid tumors and schwannomatosis, 
Van den Munckhof et al. [van den Munckhof et al., 2012] identified SMARCB1 mutations in 
families with multiple meningiomas of the falx cerebri of the cranium. Loss of function 
mutations in the SMARCE1 gene have recently been described in several families with 
multiple meningiomas of the spine [Smith et al., 2013], suggesting that a genotype-
phenotype correlation exists between histology, anatomic location and gene mutation. 
Reports of SMARCE1 mutations in breast cancer cell lines [Kiskinis et al., 2006], as well as 
in a primary breast tumor [Villaronga et al., 2011], make it likely that germline mutations in 
SMARCE1 will ultimately arise in other tumor types.
Cancer predisposition associated with SMARCA4 mutations
SMARCB1 is the primary gene associated with rhabdoid tumors of the brain, kidney and 
extra-renal sites. In fact, homozygous inactivation of this locus appears to be sufficient for 
tumorigenesis, as whole exome sequencing of primary tumors failed to identify any 
additional non-random coding sequence mutations [Lee et al., 2012]. A second rhabdoid 
tumor locus was identified when germline and somatic mutations in SMARCA4 were found 
in a small number of patients with rhabdoid tumors who did not have SMARCB1 loss 
[Schneppenheim et al., 2010; Hasselblatt et al., 2011; Witkowski et al., 2013]. As shown in 
Table 1, a wide variety of solid tumors demonstrate missense and loss of function alterations 
in SMARCA4. To date, the only other tumor type to demonstrate bi-allelic inactivation of 
SMARCA4, consistent with a cancer predisposing germline mutation and second somatic 
alteration, is small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) [Ramos et 
al., 2014; Witkowski et al., 2014; Jelinic et al., 2014]. Based on the relatively early age at 
presentation, and the presence of rhabdoid appearing cells by histology, it has been proposed 
that SCCOHT represents another type of extra-renal rhabdoid tumor [Foulkes et al., 2014]. 
The germline mutations in SCCOHT included both missense and truncating mutations, 
typically with loss of the wild-type allele as the second inactivating event in the tumor. In 
contrast to the typical findings in tumors, and similar to SMARCB1 mutations, the 
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SMARCA4 mutations in developmental disorders are all missense, non-truncating mutations, 
or in-frame deletions, as described in the accompanying papers in this issue.
Germline mutations in PBRM1 associated with clear cell sarcoma of the 
kidney
Varela et al. [Varela et al., 2011] were the first to describe PBRM1 mutations in renal cell 
carcinoma, which were highly associated with the clear cell subtype. Patients with and 
without germline VHL mutations, which characterize the majority of renal cell carcinomas, 
demonstrated somatic PBRM1 mutations, initially suggesting that PBRM1 mutations may 
have been a later genetic event in tumor development. Both genes map to 3p, thus deletions 
of 3p in tumors would unmask recessive mutations in both VHL and PBRM1. A subsequent 
report by Pena-Llopis [Pena-Llopis et al., 2012] described germline mutations of PBRM1 in 
five patients with clear cell renal cell carcinoma, including four frameshift and one missense 
mutation. Intriguingly, three of these patients also had germline mutations in VHL. The 
occurrence of germline mutations in two different cancer predisposition genes is highly 
unusual. The identification of somatic BAP1 mutations in renal cell carcinoma [Pena-Llopis 
et al., 2012], also in tumors with PBRM1 or VHL mutations, was also interesting given that 
BAP1 is a cancer predisposition gene. BAP1 and PBRM1 mutations were most often 
mutually exclusive, however those tumors with PBRM1 and BAP1 mutations had rhabdoid 
features, and BAP1 loss was associated with a higher grade, compared with those tumors 
with PBRM1 loss. As shown in Table 1, mutations in PBRM1 have been described in a 
variety of other carcinomas, raising the possibility that germline alterations could contribute 
to a broader spectrum of cancers.
Somatic mutations in SWI/SNF complex components
A shown in Table 1 and Figure 1, mutations in multiple members of the SWI/SNF complex 
have been found in human cancers including non-small cell lung cancer (NSCLC), ovarian 
carcinomas and renal cell carcinomas [Fukuoka et al., 2004; Medina et al., 2004; Medina et 
al., 2008; Reisman et al., 2003; Rodriguez-Nieto et al., 2011; Weissman and Knudsen, 2009; 
Wilson and Roberts, 2011]. Indeed, Kadoch et al. and Wang et al. recently reported that 
~20% of all human tumors show mutations in SWI/SNF components [Kadoch et al., 2013; 
Wang et al., 2014b]. Table 1 provides an overview of the range of mutations found in 
primary tumors, not including cell lines and xenografts, originating in a broad spectrum of 
human tissues.
The ubiquitous presence of SWI/SNF complex mutations in human cancer raises several 
fundamental questions about their roles in human tumor development. For example, in yeast, 
loss of any complex component yields similar phenotypes [Laurent et al., 1991; Peterson 
and Herskowitz, 1992; Wang et al., 1996]. However, it seems clear that loss of different 
SWI/SNF complex members in humans gives rise to different spectra of tumors. Therefore, 
how does the loss of each individual complex member affect the activity of the remaining 
SWI/SNF complexes? Potential mechanisms include altered nucleosome positioning 
induced by absent or aberrant SWI/SNF complex activity that lead to changes in DNA 
accessibility for RNA polymerase II or transcription factors [Kuwahara et al., 2013; 
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Tolstorukov et al., 2013], secondary effects on histone modifications through altered 
interactions with histone mark readers, writers and erasers [Hargreaves and Crabtree, 2011], 
and direct or indirect effects on DNA methylation [Berdasco and Esteller, 2013; Banine et 
al., 2005]. Once we have a better understanding of these mechanisms, we can address a 
second important issue- the different effects of complex activities between complete loss of 
a complex member versus the consequences of missense mutations. Whether the missense 
mutations in complex members found in developmental disorders represent another 
mechanism for complete loss of activity or the acquisition of new SWI/SNF functions 
remains an exciting and open question.
Genetically engineered mouse models of Smarcb1/Snf5 and other complex 
member loss
Murine models in which Smarcb1/Snf5 was knocked out in various cell types confirmed that 
homozygous loss of the locus results in embryonic lethality, and that heterozygous carriers 
developed tumors following somatic loss of the wild-type allele [Guidi et al., 2001; 
Klochendler-Yeivin et al., 2000; Roberts et al., 2000; Roberts et al., 2002]. Although the 
tumors formed in the Smarcb1+/− mice resembled the histopathology of human rhabdoid 
tumors, they occurred after a long latency period (>7 months) with a low penetrance (10–
30%) [Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Roberts et al., 2000]. Considering 
the absence of mutations of well-established oncogenes and tumor suppressor genes in 
human rhabdoid tumors, additional studies have examined the effects of Smarcb1 
inactivation in tandem with other cancer-driving genes [Lee et al., 2012]. While Smarcb1 
loss in the absence of the Tp53 tumor suppressor gene resulted in a dramatic acceleration of 
tumor development, concomitant loss of Smarcb1 and Rb or p16INK4A did not affect MRT 
development [Isakoff et al., 2005; Klochendler-Yeivin et al., 2006]. However, inactivation 
of the Rb family of genes gene through the expression of a truncated form of T antigen 
resulted in an increased tumor penetrance of neural system tumors in spinal cords or brains 
depending upon the genetic background [Chai et al., 2007; Kuwahara et al., 2012]. In 
contrast, simultaneous loss of Smarcb1 with Ccnd1, Ezh2 or Smarca4/Brg1 either 
suppressed or eliminated tumor development in mouse models [Tsikitis et al., 2005; Wang et 
al., 2009; Wilson et al., 2010]. The virtual loss of tumor development in the absence of 
EZH2 emphasizes the strong interactions between the Polycomb and SWI/SNF complexes 
while the effects of SMARCA4 loss suggests that the residual SWI/SNF complexes lacking 
SMARCB1 may gain oncogenic activity.
Similar to the Smarcb1 genetically engineered mouse model (GEMMs), homozygous 
knockout of Smarca4, Srg3/Smarcc1/Baf155 and Pbrm1/Baf180 mice show embryonic 
lethality [Bultman et al., 2000; Han et al., 2008; Wang et al., 1999]. However, rhabdoid 
tumors have not appeared in knockouts of other family members including Smarca4 
[Bultman et al., 2000; Bultman et al., 2007], Brm/Smarca2 [Reyes et al., 1998] or Baf155/
Smarcc1/Srg3 [Han et al., 2008]. Instead, loss of Smarca4 in GEMMs contributes to the 
development of mammary, lung and uterine tumors as well as ovarian cysts [Bultman et al., 
2007; Glaros et al., 2008; Serber et al., 2012; von Figura et al., 2014]. Loss of Smarca2 has 
been associated with lung and prostate tumor development while Smarcc1 inactivation 
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results in mainly sarcomas [Ahn et al., 2010; Glaros et al., 2007; Shen et al., 2008]. A tumor 
phenotype has not been reported for GEMMs involving Pbrm1/Baf180 inactivation. The 
reports that heterozygous knockout mice of different SWI/SNF complexes develop 
divergent tumors appear consistent with the observed differences in tumor specificity found 
in humans with germline mutations in complex members (see above). The mechanisms that 
drive these differences remain unknown but may result from the different types of SWI/SNF 
complexes remaining in the absence of each unique component. The association between 
complex member loss and the appearance of specific tumors may also reflect their individual 
roles in the development of specific tissues. This notion would potentially link tumor 
development with the appearance of developmental disorders found in individuals with 
germline missense mutations in complex components.
With the development of a GEMM expressing a conditional knockout allele of Smarcb1, 
attempts were made to define a cell of origin for rhabdoid tumors. However, GEMMs with 
tissue-restricted inactivation of Smarcb1 either developed aggressive lymphomas [Roberts et 
al., 2002; Isakoff et al., 2005] or led to developmental blocks [Gresh et al., 2005]. Although 
these approaches have not yet proved successful, based upon the complex histology and 
immunophenotypic profiles of the tumors, our current hypothesis proposes that rhabdoid 
tumors arise from a primitive stem cell.
Future perspectives
The large volume of high impact publications during the past 15 years emphasize that 
mutations in the SWI/SNF complex play a key role in a broad spectrum of human diseases. 
Not surprisingly, a complex that regulates central and essential features of cellular functions, 
including chromatin organization, RNA transcription, DNA damage response and meiosis, 
may provide a significant challenge for understanding its roles in developmental disorders 
and cancer. The fact that we have not fully identified the number and composition of 
SWI/SNF complexes in normal human tissues further exacerbates this problem. However, 
the studies discussed in this special issue can provide a framework in which to tackle these 
issues. As more high-throughput gene sequencing and gene expression studies become 
available along with the identification of protein constituents of individual complexes 
through proteomic advances, we should gain new insights in the complex’s normal and 
aberrant activities. Combined with better cell culture models and expansion of GEMMs, we 
can use these data to develop rational treatments for these important human diseases.
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BAF and PBAF complexes. The subunits specific to the BAF complex including ARID1A 
and ARID1B and to the PBAF complex including ARID2 and PBRM1 are demonstrated in 
the cartoon rendition of the complexes. Mutations in subunits colored in blue have been 
demonstrated in the literature to be associated with cancer, and subunits with mutations that 
have been associated with either cancer and/or known genetic disorders (i.e. Coffin-Siris 
syndrome) are colored in purple.
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Germline SMARCB1 alterations in patients with rhabdoid tumor. Deletions of SMARCB1, 
both whole gene (22%) and intragenic (24%), encompass the majority of the germline 
alterations observed in rhabdoid tumors. A large percentage of the remaining germline 
alterations observed in SMARCB1 are frameshift mutations (20%) followed by nonsense 
mutations (17%). A smaller percentage of germline SMARCB1 alterations result from splice 
site mutations (10%) and partial gene duplications (7%).
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